Coherus Oncology, Inc. (CHRS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-09

Key Insights

Coherus Oncology, Inc. reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's performance.
The company's press release indicates that it experienced growth in both quarterly and annual revenue, suggesting positive momentum in its business.
However, the filing does not provide detailed financial figures or guidance for the upcoming year, limiting the ability to fully assess the company's financial health and future prospects.

Want the newest filings?

This analysis covers the filing from 2026-03-09. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-17

Coherus Oncology, Inc. (CHRS) completed a public offering of 28.6 million shares of common stock, raising approximately $47 million in net proceeds.
The company granted the underwriters an option to purchase up to an additional 4.29 million shares to cover any over-allotments.
Coherus Oncology, its directors, executive officers, and certain affiliated stockholders have agreed to a 60-day lock-up period on selling or transferring shares, subject to certain exceptions.

Filed: 2026-02-04

Coherus Oncology, Inc. has entered into a clinical supply agreement with Janssen to evaluate their investigational anti-CCR8 cytolytic monoclonal antibody, tagmokitug, in combination with Janssen's T-cell engaging bispecific antibody, pasritamig, in a Phase 1b clinical study for metastatic castration-resistant prostate cancer (mCRPC).
Under the terms of the agreement, Janssen will provide pasritamig to Coherus, who will be the sponsor of the Phase 1b trial, while both companies retain commercial rights to their respective compounds.
This collaboration could potentially lead to the development of a novel combination therapy for mCRPC, which is an important area of unmet medical need.

Filed: 2026-01-23

Coherus Oncology has filed a prospectus supplement to sell up to $64.88 million worth of common stock through a sales agreement with TD Cowen, providing additional funding for the company.
The company has made several amendments to the sales agreement since it was initially established in 2022, indicating ongoing flexibility and adaptability in its capital raising strategy.
The legal opinion from Latham & Watkins LLP regarding the validity of the stock issuance suggests that the company is taking the necessary steps to ensure compliance and transparency for investors.

Filed: 2026-01-13

Coherus Oncology provided preliminary unaudited financial results for Q4 2025 and FY 2025, including net revenues and cash/investments as of December 31, 2025.
The company's preliminary financial results are not final and may change significantly based on the completion of the full financial closing procedures.
Coherus Oncology cautioned that the preliminary results have not been reviewed or audited by its independent registered public accounting firm.

Other reports for Coherus Oncology, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.